Revenue
2022
2023
2024
2025
Regentis Biomaterials Ltd. (RGNT)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $331,000 | −$1.6M | $806,000 | $971,000 | — |
| Operating expenses | $8.6M | −$932,000 | $1.9M | $1.4M | — |
| Operating income | −$7.0M | $932,000 | −$1.9M | −$1.4M | — |
| EBITDA | −$13.3M | $5.0M | −$4.0M | −$1.4M | — |
| Net income | −$13.6M | $4.8M | −$4.1M | −$1.4M | — |
| Basic EPSper basic share | -$24.16 | $1.72 | -$24.09 | -$0.29 | -$1.00 |
| Diluted EPSper diluted share | -$24.16 | $1.72 | -$24.09 | -$0.29 | -$1.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Rosalind Advisors, Inc. | 701.69K |
Ben-Elazar Pini | 128.67K |
Warberg Asset Management LLC | 86.98K |
JANE STREET GROUP, LLC | 43.33K |
RENAISSANCE TECHNOLOGIES LLC | 13.35K |
UBS Group AG | 434 |
Tower Research Capital LLC (TRC) | 11 |
Dykan Jeff | — |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data